The Rybrevant combination therapy by Johnson & Johnson (J&J) continues to be effective after three years in a study of patients with non-small cell lung cancer (NSCLC).
New data from the Phase III MARIPOSA study (NCT04487080) showed a strong and improving overall survival (OS) benefit from Rybrevant (amivantamab-vmjw) combined with Lazcluze (lazertinib) at three years, with data presented during the International Association for the Study of Lung Cancer (IASLC) 2024 World Conference on Lung Cancer (WCLC) in San Diego, US.
At three years, 61% of patients on the combination therapy reached overall survival (OS) compared to 53% of patients in the Tagrisso (osimertinib) comparator arm. OS will continue to be assessed with longer-term follow-up.
Results also showed Rybrevant and Lazcluze improved central nervous system disease control compared to Tagrisso at three years.
At the three-year landmark, intracranial progression-free survival (PFS) was doubled with Rybrevant plus Lazcluze at 38% versus Tagrisso at 18%.
Finally, 45% of patients receiving the combination therapy had not started a subsequent therapy after three years versus 32% of Tagrisso patients, with PFS higher in the treatment group than those who received subsequent therapy.
The safety profile remained consistent with the earlier data, with a 10% discontinuation rate in the treatment arm.
Dr Joshua Bauml, vice president, lung cancer disease area stronghold leader at J&J, said: “Promising results like these presented at WCLC reinforce our mission to improve the lives of patients diagnosed with lung cancer.
“We are encouraged by the favourable overall survival trend observed with Rybrevant and Lazcluze and are eager to see how these data evolve as we continue to follow patients over time."
The Phase III trial previously showed that first-line treatment with Rybrevant and Lazcluze was better than Tagrisso monotherapy in patients with advanced NSCLC with epidermal growth factor receptor (EGFR) exon 19 deletions (ex19del) or L858R substitution mutations.
Last month, the combination of Rybrevant and Lazcluze was approved following a priority review by the US Food and Drug Administration as a first-line therapy for this patient group.
AstraZeneca’s Tagrisso is currently the first line, standard of care for patients with locally advanced or metastatic EGFR mutated NSCLC.
